Could biomarkers of bone, cartilage or synovium turnover be used for relapse prediction in rheumatoid arthritis patients?

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Dénarié, Delphine ^a   Constant, Elodie ^a   Thomas, Thierry ^a   Marotte, Hubert ^a  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARTILAGE OLIGOMERIC MATRIX PROTEIN; COLLAGEN; COLLAGEN TYPE 2C TELOPEPTIDE; COLLAGEN TYPE 3; GLUCOSYL GALACTOSYL PYRIDINOLINE; MEMBRANE PROTEIN; N TELOPEPTIDE OF TYPE III COLLAGEN; PYRIDINOLINE; STROMELYSIN; TRACP 5B PROTEIN; UNCLASSIFIED DRUG;

BONE TURNOVER; CARTILAGE TURNOVER; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; HUMAN; JOINT DESTRUCTION; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM; SYNOVIUM TURNOVER; TURNOVER TIME; ARTHRITIS, RHEUMATOID; BONE; CARTILAGE; METABOLISM; PATHOPHYSIOLOGY; RECURRENT DISEASE;

ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BONE AND BONES; CARTILAGE; DISEASE PROGRESSION; HUMANS; RECURRENCE; REMISSION INDUCTION; SYNOVIAL MEMBRANE;

EID: 84897540876     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/537324     Document Type: Review

References (71)

1. Abdel-Nasser A. M., Rasker J. J., Valkenburg H. A., Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis. Seminars in Arthritis and Rheumatism 1997 27 2 123 140 2-s2.0-0030785532 10.1016/S0049-0172(97)80012-1 (Pubitemid 27461157)
2. Mathieux R., Marotte H., Battistini L., Sarrazin A., Berthier M., Miossec P., Early occupational therapy programme increases hand grip strength at 3 months: results from a randomised, blind, controlled study in early rheumatoid arthritis. Annals of the Rheumatic Diseases 2009 68 3 400 403 2-s2.0-61449242858 10.1136/ard.2008.094532
3. Scott D. L., Pugner K., Kaarela K., Doyle D. V., Woolf A., Holmes J., Hieke K., The links between joint damage and disability in rheumatoid arthritis. Rheumatology 2000 39 2 122 132 2-s2.0-0034104307 (Pubitemid 30139344)
4. Pincus T., Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. Journal of Clinical Epidemiology 1988 41 11 1037 1041 2-s2.0-0024208901 (Pubitemid 19037931)
5. Emery P., Breedveld F. C., Dougados M., Kalden J. R., Schiff M. H., Smolen J. S., Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Annals of the Rheumatic Diseases 2002 61 4 290 297 2-s2.0-0036210080 10.1136/ard.61.4.290 (Pubitemid 34257737)
6. O'Dell J. R., Treating rheumatoid arthritis early: a window of opportunity? Arthritis and Rheumatism 2002 46 2 283 285 2-s2.0-0036166461 10.1002/art.10092 (Pubitemid 34136564)
7. Schett G., Firestein G. S., Mr Outside and Mr Inside: classic and alternative views on the pathogenesis of rheumatoid arthritis. Annals of the Rheumatic Diseases 2010 69 5 787 789 2-s2.0-77951545407 10.1136/ard.2009.121657
8. Fouque-Aubert A., Boutroy S., Marotte H., Vilayphiou N., Bacchetta J., Miossec P., Delmas P. D., Chapurlat R. D., Assessment of hand bone loss in rheumatoid arthritis by high-resolution peripheral quantitative CT. Annals of the Rheumatic Diseases 2010 69 9 1671 1676 2-s2.0-77956046554 10.1136/ard.2009.114512
9. Van Leeuwen M. A., Van Rijswijk M. H., Van der Heijde D. M. F. M., Te Meerman G. J., Van Riel P. L. C. M., Houtman P. M., Van de Putte L. B. A., Limburg P. C., The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. British Journal of Rheumatology 1993 32 6 9 13 2-s2.0-0027252478 (Pubitemid 23193420)
10. Redlich K., Hayer S., Maier A., Dunstan C. R., Tohidast-Akrad M., Lang S., Türk B., Pietschmann P., Woloszczuk W., Haralambous S., Kollias G., Steiner G., Smolen J. S., Schett G., Tumor necrosis factor α -mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis and Rheumatism 2002 46 3 785 792 2-s2.0-0036185343 10.1002/art.10097 (Pubitemid 34214261)
11. Zwerina J., Hayer S., Tohidast-Akrad M., Bergmeister H., Redlich K., Feige U., Dunstan C., Kollias G., Steiner G., Smolen J., Schett G., Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis and Rheumatism 2004 50 1 277 290 2-s2.0-9144261181 10.1002/art.11487 (Pubitemid 38084313)
12. Karsdal M. A., Bay-Jensen A. C., Leeming D. J., Henriksen K., Christiansen C., Quantification of "end products" of tissue destruction in inflammation may reflect convergence of cytokine and signaling pathways-implications for modern clinical chemistry. Biomarkers 2013 18 5 375 378
13. Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Weisman M., Emery P., Feldmann M., Harriman G. R., Maini R. N., Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. The New England Journal of Medicine 2000 343 22 1594 1602
14. Genovese M. C., Bathon J. M., Martin R. W., Fleischmann R. M., Tesser J. R., Schiff M. H., Keystone E. C., Wasko M. C., Moreland L. W., Weaver A. L., Markenson J., Cannon G. W., Spencer-Green G., Finck B. K., Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis and Rheumatism 2002 46 6 1443 1450 2-s2.0-0036274944 10.1002/art.10308 (Pubitemid 34620189)
15. Keystone E. C., Kavanaugh A. F., Sharp J. T., Tannenbaum H., Hua Y., Teoh L. S., Fischkoff S. A., Chartash E. K., Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis and Rheumatism 2004 50 5 1400 1411 2-s2.0-2342658406 10.1002/art.20217 (Pubitemid 38608061)
16. Felson D. T., Smolen J. S., Wells G., Zhang B., Van Tuyl L. H. D., Funovits J., Aletaha D., Allaart C. F., Bathon J., Bombardieri S., Brooks P., Brown A., Matucci-Cerinic M., Choi H., Combe B., De Wit M., Dougados M., Emery P., Furst D., Gomez-Reino J., Hawker G., Keystone E., Khanna D., Kirwan J., Kvien T. K., Landewé R., Listing J., Michaud K., Martin-Mola E., Montie P., Pincus T., Richards P., Siegel J. N., Simon L. S., Sokka T., Strand V., Tugwell P., Tyndall A., Van Der Heijde D., Verstappen S., White B., Wolfe F., Zink A., Boers M., American college of rheumatology/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis and Rheumatism 2011 63 3 573 586 2-s2.0-79953752083 10.1002/art.30129
17. Lillegraven S., Prince F. H. M., Shadick N. A., Bykerk V. P., Lu B., Frits M. L., Iannaccone C. K., Kvien T. K., Haavardsholm E. A., Weinblatt M. E., Solomon D. H., Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Annals of the Rheumatic Diseases 2012 71 5 681 686 2-s2.0-84859517687 10.1136/ard.2011.154625
18. Foltz V., Gandjbakhch F., Etchepare F., Rosenberg C., Tanguy M. L., Rozenberg S., Bourgeois P., Fautrel B., Power doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity. Arthritis and Rheumatism 2012 64 1 67 76 2-s2.0-84855269285 10.1002/art.33312
19. Quinn M. A., Conaghan P. G., O'Connor P. J., Karim Z., Greenstein A., Brown A., Brown C., Fraser A., Jarret S., Emery P., Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism 2005 52 1 27 35 2-s2.0-19944431840 10.1002/art.20712 (Pubitemid 40129229)
20. Karsdal M. A., Woodworth T., Henriksen K., Maksymowych W. P., Genant H., Vergnaud P., Christiansen C., Schubert T., Qvist P., Schett G., Platt A., Bay-Jensen A.-C., Biochemical markers of ongoing joint damage in rheumatoid arthritis-current and future applications, limitations and opportunities. Arthritis Research and Therapy 2011 13 2, article 215 2-s2.0-82155192252 10.1186/ar3280
21. Isaacs J. D., Ferraccioli G., The need for personalised medicine for rheumatoid arthritis. Annals of the Rheumatic Diseases 2011 70 1 4 7 2-s2.0-78650677911 10.1136/ard.2010.135376
22. Okada Y., Nagase H., Harris E. D. Jr., A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization. The Journal of Biological Chemistry 1986 261 30 14245 14255 2-s2.0-0023024460 (Pubitemid 17196334)
23. Walakovits L. A., Moore V. L., Bhardwaj N., Gallick G. S., Lark M. W., Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis and Rheumatism 1992 35 1 35 42 2-s2.0-0026604634
24. Gravallese E. M., Darling J. M., Ladd A. L., Katz J. N., Glimcher L. H., In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium. Arthritis and Rheumatism 1991 34 9 1076 1084 2-s2.0-0026051828 10.1002/art.1780340903
25. Constantin A., Lauwers-Cancès V., Navaux F., Abbal M., Van Meerwijk J., Mazières B., Cambon-Thomsen A., Cantagrel A., Stromelysin 1 (matrix metalloproteinase 3) and HLA-DRB1 gene polymorphisms: association with severity and progression of rheumatoid arthritis in a prospective study. Arthritis and Rheumatism 2002 46 7 1754 1762 2-s2.0-0036065025 10.1002/art.10336 (Pubitemid 34774506)
26. Chen Y., Nixon N. B., Dawes P. T., Mattey D. L., Influence of variations across the MMP-1 and-3 genes on the serum levels of MMP-1 and-3 and disease activity in rheumatoid arthritis. Genes and Immunity 2012 13 1 29 37 2-s2.0-84855972119 10.1038/gene.2011.46
27. Yamanaka H., Matsuda Y., Tanaka M., Sendo W., Nakajima H., Taniguchi A., Kamatani N., Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis & Rheumatology 2000 43 4 852 858
28. Garnero P., Gineyts E., Christgau S., Finck B., Delmas P. D., Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis & Rheumatology 46 1 21 30
29. Mamehara A., Sugimoto T., Sugiyama D., Morinobu S., Tsuji G., Kawano S., Morinobu A., Kumagai S., Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs. Kobe Journal of Medical Sciences 2010 56 3 E98 E107 2-s2.0-77958568501
30. Ally M. M. T. M., Hodkinson B., Meyer P. W. A., Musenge E., Tikly M., Anderson R., Serum matrix metalloproteinase-3 in comparison with acute phase proteins as a marker of disease activity and radiographic damage in early rheumatoid arthritis. Mediators of Inflammation 2013 2013 6 183653 10.1155/2013/183653
31. Houseman M., Potter C., Marshall N., Lakey R., Cawston T., Griffiths I., Young-Min S., Isaacs J. D., Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. Arthritis Research and Therapy 2012 14 1, article R30 2-s2.0-84856582992 10.1186/ar3734
32. Huang J., Xie B., Li Q., Xie X., Zhu S., Wang M., Peng W., Gu J., Infliximab reduces CD147, MMP-3, and MMP-9 expression in peripheral blood monocytes in patients with active rheumatoid arthritis. European Journal of Pharmacology 2013 698 1-3 429 434
33. Weinblatt M. E., Keystone E. C., Furst D. E., Moreland L. W., Weisman M. H., Birbara C. A., Teoh L. A., Fischkoff S. A., Chartash E. K., Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis and Rheumatism 2003 48 1 35 45 2-s2.0-0037231533 10.1002/art.10697 (Pubitemid 36091645)
34. Funahashi K., Koyano S., Miura T., Hagiwara T., Okuda K., Matsubara T., Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level. Modern Rheumatology 2009 19 5 507 512 2-s2.0-70350028295 10.1007/s10165-009-0203-z
35. Kanbe K., Chiba J., Nakamura A., Immunohistological analysis of synovium treated with abatacept in rheumatoid arthritis. Rheumatology International 2013 33 7 1883 1887 2-s2.0-84855166061 10.1007/s00296-011-2326-8
36. Urata Y., Uesato R., Tanaka D., Nakamura Y., Motomura S., Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study. Annals of the Rheumatic Diseases 2012 71 4 534 540 2-s2.0-84857856429 10.1136/annrheumdis-2011-200108
37. Kawashiri S.-Y., Kawakami A., Ueki Y., Imazato T., Iwamoto N., Fujikawa K., Aramaki T., Tamai M., Nakamura H., Origuchi T., Ida H., Eguchi K., Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab. Joint Bone Spine 2010 77 5 418 420 2-s2.0-77957885947 10.1016/j.jbspin.2010.01.016
38. Nishimoto N., Amano K., Hirabayashi Y., Horiuchi T., Ishii T., Iwahashi M., Iwamoto M., Kohsaka H., Kondo M., Matsubara T., Mimura T., Miyahara H., Ohta S., Saeki Y., Saito K., Sano H., Takasugi K., Takeuchi T., Tohma S., Tsuru T., Ueki Y., Yamana J., Hashimoto J., Matsutani T., Murakami M., Takagi N., Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Modern Rheumatology 2014 24 no1 17 25
39. Gineyts E., Garnero P., Delmas P. D., Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation. Rheumatology 2001 40 3 315 323 2-s2.0-0035057739
40. Takahashi M., Kushida K., Hoshino H., Suzuki M., Sano M., Miyamoto S., Inoue T., Concentrations of pyridinoline and deoxypyridinoline in joint tissues from patients with osteoarthritis or rheumatoid arthritis. Annals of the Rheumatic Diseases 1996 55 5 324 327 2-s2.0-0029938126 (Pubitemid 26166265)
41. Marotte H., Gineyts E., Miossec P., Delmas P. D., Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2009 68 7 1197 1200 2-s2.0-67549119580 10.1136/ard.2008.096057
42. Sandhu J. K., Robertson S., Birnboim H. C., Goldstein R., Distribution of protein nitrotyrosine in synovial tissues of patients with rheumatoid arthritis and osteoarthritis. Journal of Rheumatology 2003 30 6 1173 1181 2-s2.0-0037981344 (Pubitemid 36666337)
43. Richardot P., Charni-Ben Tabassi N., Toh L., Marotte H., Bay-Jensen A.-C., Miossec P., Garnero P., Nitrated type III collagen as a biological marker of nitric oxide-mediated synovial tissue metabolism in osteoarthritis. Osteoarthritis and Cartilage 2009 17 10 1362 1367 2-s2.0-70349386224 10.1016/j.joca.2009.04.024
44. Tabassi N. C.-B., Richardot P., Toh L., Marotte H., Bay-Jensen A.-C., Miossec P., Garnero P., Circulating nitrated N-telopeptide of type III collagen (IIINys) as a biochemical marker of oxidative-related synovial tissue metabolism in rheumatoid arthritis. Annals of the Rheumatic Diseases 2009 68 3 451 452 2-s2.0-61449124077 10.1136/ard.2008.097915
45. Goldring M. B., Marcu K. B., Cartilage homeostasis in health and rheumatic diseases. Arthritis Research and Therapy 2009 11 3, article 224 2-s2.0-66249096001 10.1186/ar2592
46. Christgau S., Garnero P., Fledelius C., Moniz C., Ensig M., Gineyts E., Rosenquist C., Qvist P., Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001 29 3 209 215 2-s2.0-0034852317 10.1016/S8756-3282(01)00504-X (Pubitemid 32823562)
47. Garnero P., Landewé R., Boers M., Verhoeven A., Van Der Linden S., Christgau S., Van Der Heijde D., Boonen A., Geusens P., Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis and Rheumatism 2002 46 11 2847 2856 2-s2.0-0036846269 10.1002/art.10616 (Pubitemid 35315875)
48. Saxne T., Heinegard D., Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. British Journal of Rheumatology 1992 31 9 583 591 2-s2.0-0026660250
49. Andersson M. L. E., Svensson B., Petersson I. F., Hafström I., Albertsson K., Forslind K., Heinegård D., Saxne T., Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis. BMC Musculoskeletal Disorders 2013 14 229
50. Christensen A. F., Lottenburger T., Lindegaard H. M., Junker K., Hørslev-Petersen K., Junker P., Circadian pattern and the effect of standardized physical exercise on procollagen IIA N-peptide (PIIANP) in rheumatoid arthritis at different stages and in healthy individuals. Biomarkers 2010 15 1 80 85 2-s2.0-75749113243 10.3109/13547500903302927
51. Seeman E., Delmas P. D., Bone quality-the material and structural basis of bone strength and fragility. The New England Journal of Medicine 2006 354 21 2212 2261 2-s2.0-33646889773 10.1056/NEJMra053077
52. Garnero P., Ferreras M., Karsdal M. A., Nicamhlaoibh R., Risteli J., Borel O., Qvist P., Delmas P. D., Foged N. T., Delaissé J. M., The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. Journal of Bone and Mineral Research 2003 18 5 859 867 2-s2.0-10744225319 10.1359/jbmr.2003.18.5.859 (Pubitemid 37294969)
53. Sassi M.-L., Eriksen H., Risteli L., Niemi S., Mansell J., Gowen M., Risteli J., Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 2000 26 4 367 373 2-s2.0-0034012685 10.1016/S8756-3282(00) 00235-0 (Pubitemid 30136127)
54. Garnero P., Delmas P. D., Noninvasive techniques for assessing skeletal changes in inflammatory arthritis: bone biomarkers. Current Opinion in Rheumatology 2004 16 4 428 434 2-s2.0-3042668915 10.1097/01.moo.0000127830. 72761.00 (Pubitemid 38803145)
55. Garnero P., Jouvenne P., Buchs N., Delmas P. D., Miossec P., Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products. Bone 1999 24 4 381 385 2-s2.0-0033120581 10.1016/S8756-3282(98)00193-8 (Pubitemid 29134976)
56. Fouque-Aubert A., Boutroy S., Marotte H., Vilayphiou N., Bacchetta J., Miossec P., Delmas P. D., Chapurlat R. D., Assessment of hand bone loss in rheumatoid arthritis by high-resolution peripheral quantitative CT. Annals of the Rheumatic Diseases 2010 69 9 1671 1676 2-s2.0-77956046554 10.1136/ard.2009.114512
57. Aschenberg S., Finzel S., Schmidt S., Kraus S., Engelke K., Englbrecht M., Rech J., Schett G., Catabolic and anabolic periarticular bone changes in patients with rheumatoid arthritis: a computed tomography study on the role of age, disease duration and bone markers. Arthritis Research & Therapy 2013 15 3 R62
58. Krabben A., Knevel R., Huizinga T. W. J., Cavet G., van der Helm-van A. H. M., Serum pyridinoline levels and prediction of severity of joint destruction in rheumatoid arthritis. The Journal of Rheumatology 2013 40 8 1303 1306
59. Le Loët X., Brazier M., Mejjad O., Boumier P., Daragon A., Gayet A., Pouplin S., Tron F., Zarnitsky C., Vittecoq O., Menard J.-F., Fardellone P., Serum IgA rheumatoid factor and pyridinoline in very early arthritis as predictors of erosion(s) at two years: a simple model of prediction from a conservatively treated community-based inception cohort. Arthritis care & research 2010 62 12 1739 1747 2-s2.0-79952115923
60. Chopin F., Garnero P., Le Henanff A., Debiais F., Daragon A., Roux C., Sany J., Wendling D., Zamitsky C., Ravaud P., Thomas T., Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2008 67 3 353 357 2-s2.0-39549116297 10.1136/ard.2007.076604 (Pubitemid 351281270)
61. Marotte H., Miossec P., Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNF α therapy. Biologics 2008 2 4 663 669 2-s2.0-77953994146
62. Vis M., Havaardsholm E. A., Haugeberg G., Uhlig T., Voskuyl A. E., Van De Stadt R. J., Dijkmans B. A. C., Woolf A. D., Kvien T. K., Lems W. F., Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NF B ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2006 65 11 1495 1499 2-s2.0-33749150667 10.1136/ard.2005.044198 (Pubitemid 44629129)
63. Karsdal M. A., Schett G., Emery P., Harari O., Byrjalsen I., Kenwright A., Bay-Jensen A. C., Platt A., IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Seminars in Arthritis and Rheumatism 2012 42 2 131 139 2-s2.0-84857660096 10.1016/j.semarthrit.2012. 01.004
64. Bekker P. J., Holloway D. L., Rasmussen A. S., Murphy R., Martin S. W., Leese P. T., Holmes G. B., Dunstan C. R., DePaoli A. M., A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004. Journal of Bone and Mineral Research 2005 20 12 2275 2282 2-s2.0-33644849960
65. Cohen S. B., Dore R. K., Lane N. E., Ory P. A., Peterfy C. G., Sharp J. T., Van Der Heijde D., Zhou L., Tsuji W., Newmark R., Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis and Rheumatism 2008 58 5 1299 1309 2-s2.0-43949139580 10.1002/art.23417 (Pubitemid 351705919)
66. Peabody J. W., Strand V., Shimkhada R., Lee R., Chernoff D., Impact of rheumatoid arthritis disease activity test on clinical practice. PloS ONE 2013 8 5 10.1371/journal.pone.0063215
67. Hirata S., Dirven L., Shen Y., Centola M., Cavet G., Lems W. F., Tanaka Y., Huizinga T. W. J., Allaart C. F., A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology 2013 52 7 1202 1207
68. van der Helm-van A. H. M., Knevel R., Cavet G., Huizinga T. W. J., Haney D. J., An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatology 2013 52 5 839 846
69. Vermeer M., Kuper H. H., Hoekstra M., Haagsma C. J., Posthumus M. D., Brus H. L. M., Van Riel P. L. C. M., Van De Laar M. A. F. J., Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis and Rheumatism 2011 63 10 2865 2872 2-s2.0-80053545701 10.1002/art.30494
70. Miossec P., Verweij C. L., Klareskog L., Pitzalis C., Barton A., Lekkerkerker F., Reiter S., Laslop A., Breedveld F., Abadie E., Flamion B., Dere W., Mpofu S., Goel N., Ethgen D., Mitlak B., Ormarsdotóttir S., Rao R., Tsouderos Y., Reginster J.-Y., Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Annals of the Rheumatic Diseases 2011 70 10 1713 1718 2-s2.0-80052464715 10.1136/ard.2011.154252
71. Ferraccioli G., Alivernini S., Gremese E., Biomarkers of joint damage in rheumatoid arthritis: where are we in 2013? The Journal of Rheumatology 40 8 1244 1246